The present study demonstrated that treatment with dasatinib inhibited platelet adherence to tumor cells, phosphorylation of EGFR and Akt, as well as ERK, resulting in complete reversal of the high D-dimer plasma-induced TKI resistance. Here, AKT1 is linked to neoplasm.